Table 2. Treatment-Related Adverse Events Reported During Follow-up.

Toxic effect	Toxic effects by olaparib dose and toxic effect grade, No.a
	50 mg Twice daily				100 mg Twice daily				150 mg Twice daily				200 mg Twice daily
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
1-y Follow-up (n = 23)
Pain	0	0	0	0	0	1	0	0	1	0	0	0	2	0	0	0
Fibrosis	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Deformity	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Skin hyperpigmentation	0	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0
Telangiectasia	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Lymphedema	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
2-y Follow-up (n = 20)
Pain	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0
Fibrosis	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0
Deformity	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Skin hyperpigmentation	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
Telangiectasia	0	0	0	0	3	0	0	0	0	0	0	0	1	0	0	0
Lymphedema	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0

^a Toxic effect grades are based on Common Terminology Criteria for Adverse Events, version 4.03.⁹